2.68 USD
-0.08 (-2.9%)
2.75 USD
+0.07 (+2.61%)
Taking everything into account, HIND scores 2 out of 10 in our fundamental rating. HIND was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of HIND is average, but there are quite some concerns on its profitability. HIND is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- HIND had negative earnings in the past year.
- In the past year HIND has reported a negative cash flow from operations.
- HIND had negative earnings in each of the past 5 years.
- In the past 5 years HIND always reported negative operating cash flow.
1.2 Ratios
- HIND has a worse Return On Assets (-161.11%) than 87.43% of its industry peers.
- With a Return On Equity value of -448.70%, HIND is not doing good in the industry: 79.06% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.11% | ||
| ROE | -448.7% | ||
| ROIC | N/A |
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HIND has a Gross Margin of 62.39%. This is in the better half of the industry: HIND outperforms 72.25% of its industry peers.
- HIND's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for HIND so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
2. Health
2.1 Basic Checks
- HIND does not have a ROIC to compare to the WACC, probably because it is not profitable.
- HIND has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for HIND has been increased compared to 5 years ago.
- HIND has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -16.59, we must say that HIND is in the distress zone and has some risk of bankruptcy.
- HIND's Altman-Z score of -16.59 is on the low side compared to the rest of the industry. HIND is outperformed by 81.15% of its industry peers.
- HIND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.59 |
ROIC/WACCN/A
WACC9.4%
2.3 Liquidity
- HIND has a Current Ratio of 1.94. This is a normal value and indicates that HIND is financially healthy and should not expect problems in meeting its short term obligations.
- HIND has a Current ratio of 1.94. This is in the lower half of the industry: HIND underperforms 62.83% of its industry peers.
- HIND has a Quick Ratio of 1.94. This is a normal value and indicates that HIND is financially healthy and should not expect problems in meeting its short term obligations.
- HIND's Quick ratio of 1.94 is in line compared to the rest of the industry. HIND outperforms 42.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.94 |
3. Growth
3.1 Past
- HIND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.16%, which is quite impressive.
- The Revenue for HIND has decreased by -48.74% in the past year. This is quite bad
- The Revenue has been growing by 19.54% on average over the past years. This is quite good.
EPS 1Y (TTM)90.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.02%
Revenue 1Y (TTM)-48.74%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-98.49%
3.2 Future
- HIND is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -45.64% yearly.
- HIND is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y-604.44%
EPS Next 2Y-34.99%
EPS Next 3Y-45.64%
EPS Next 5YN/A
Revenue Next Year-97.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for HIND. In the last year negative earnings were reported.
- Also next year HIND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as HIND's earnings are expected to decrease with -45.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.99%
EPS Next 3Y-45.64%
5. Dividend
5.1 Amount
- HIND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.68
-0.08 (-2.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12
Earnings (Next)04-02 2026-04-02/amc
Inst Owners1.99%
Inst Owner Change0%
Ins Owners26.79%
Ins Owner Change0%
Market Cap15.12M
Revenue(TTM)4.19M
Net Income(TTM)-11.35M
Analysts82.86
Price Target15.3 (470.9%)
Short Float %2.31%
Short Ratio1.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)-161.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-780.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-97.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.98 | ||
| P/tB | 6.82 | ||
| EV/EBITDA | N/A |
EPS(TTM)-183.13
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.74
BVpS0.45
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.11% | ||
| ROE | -448.7% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.39% | ||
| FCFM | N/A |
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.94 | ||
| Altman-Z | -16.59 |
F-Score3
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.02%
EPS Next Y-604.44%
EPS Next 2Y-34.99%
EPS Next 3Y-45.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-48.74%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-98.49%
Revenue Next Year-97.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y31.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y83.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.93%
OCF growth 3YN/A
OCF growth 5YN/A
VYOME HOLDINGS INC / HIND FAQ
Can you provide the ChartMill fundamental rating for VYOME HOLDINGS INC?
ChartMill assigns a fundamental rating of 2 / 10 to HIND.
Can you provide the valuation status for VYOME HOLDINGS INC?
ChartMill assigns a valuation rating of 0 / 10 to VYOME HOLDINGS INC (HIND). This can be considered as Overvalued.
What is the profitability of HIND stock?
VYOME HOLDINGS INC (HIND) has a profitability rating of 1 / 10.
What is the financial health of VYOME HOLDINGS INC (HIND) stock?
The financial health rating of VYOME HOLDINGS INC (HIND) is 4 / 10.